JAMA Editors' Choice 2025: Clinical Revi...

Mifepristone used with misoprostol is the most common abortion regimen in the US. It is also a focal point of reproductive health policy and politics, with controversy over its legal status and regulation by the US Food and Drug Administration (FDA). Author G. Caleb Alexander, MD ... Show More

Incidence rates of gastric cancer in younger individuals are on the rise and gastric cancer is the fifth-leading cause of cancer-related deaths worldwide. JAMA Review author Haeseong Park, MD, MPH, from the Dana Farber Cancer Institute, discusses this and more with JAMA Senior Ed ... Show More

In this episode, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, and Medical News Director Jennifer Abbasi discuss the journal's inaugural Research of the Year roundup. Related Content: Research of the Year 2025 

Join Dr. Chandra as she discusses the importance of understanding the risks of obesity and how we can address the disease during National Obesity Care Week. 

The rise in obesity and chronic disease over the years is alarming. Rather than genetics, it can be attributed to environmental and dietary changes, emphasizing the role of food quality over quantity. And while GLP-1 agonists like Ozempic may show some promise in addressing metab ... Show More

<p><a href='https://www.examroomnutrition.com/course'>Join The Obesity Medicine Nutrition Course</a>! Enter code POD15 at checkout for 15% off!</p><p>Anti-obesity medications are everywhere—but they also come with new challenges. From rapid weight loss and side effects to TikTok- ... Show More

<p>This is an "ask me anything" (AMA) episode with Dr. Stephan Guyenet, an expert in obesity neuroscience and eating behavior. <strong>This episode was originally published on <a href="https://sigmanutrition.com/premium/" target= "_blank" rel="noreferrer noopener follow" data-wpe ... Show More

<p>In this episode, respected neuroscientist and author Dr. Tara Swart joins Jake to uncover fascinating perspectives about the complex interplay between our brains and bodies.</p><br><p>Tara sheds light on how our constant smartphone use impacts us both mentally and physically, ... Show More

Ozempic, Wegovy, and Mounjaro, are being called “miracle drugs” with users boasting about their fast results. Dr. Sanjay Gupta takes a deep dive into how they disrupted the entire weight loss industry and changed the conversation about obesity.  Learn more about your ad choices. ... Show More

Writer, speaker, and weight-inclusive health/fitness professional Ragen Chastain joins us to discuss the potential side effects and other downsides of using GLP-1 drugs (like Ozempic and its ilk) for weight loss, the massive influence the manufacturers of these drugs are having o ... Show More

CardioNerds (Drs. Gurleen Kaur and Richard Ferraro) and episode FIT Lead Dr. Saahil Jumkhawala (Cardiology Fellow at the University of Miami) discuss SGLT inhibitors, focusing on the biology of SGLT and its inhibition, with Dr. Katherine Tuttle (Executive Director for Research at ... Show More

Globally, 650 million people meet the threshold for obesity. With those numbers on the rise, we ask: Is obesity a matter of individual choice, or is it rooted in larger systemic problems? Greg Doucette, a bodybuilder and health coach, says that obesity is a choice, and argues tha ... Show More